The Prostate. Supplement最新文献_第8页

Estramustine phosphate and other cytotoxic drugs in the treatment of poor prognostic advanced prostate cancer. 磷酸依雌莫司汀与其他细胞毒性药物治疗预后不良的晚期前列腺癌。

The Prostate. Supplement Pub Date : 1992-01-01 DOI: 10.1002/pros.2990210516

R A Janknegt

{"title":"Estramustine phosphate and other cytotoxic drugs in the treatment of poor prognostic advanced prostate cancer.","authors":"R A Janknegt","doi":"10.1002/pros.2990210516","DOIUrl":"https://doi.org/10.1002/pros.2990210516","url":null,"abstract":"<p><p>Hormonal treatment is effective for only a limited time in primary treatment of advanced prostate cancer, because of the development of hormone-resistant cells. It is unknown whether these cells were present in small numbers from the beginning or developed later by mutation of hormone-sensitive cells. Cytotoxic therapy has, up to now, mainly been used as second-line treatment when virtually all cells are hormone-resistant. Because 20% of all advanced prostate cancers do not respond to hormonal treatment even when given as primary therapy, hormone-resistant cells may have been present from the beginning. Trials using a combined hormonal and cytotoxic treatment as primary therapy would, therefore, be interesting. However, there is a lack of active compounds that do not show major toxicity. Estramustine phosphate (EMP) may be an exception. It is unusual because it combines hormonal and cytotoxic effects. Second-line treatment with chemotherapy has led to subjective improvement over a very short period of time only. EMP may be of benefit to patients who have had previous radiotherapy as it does not suppress the bone marrow. Although primary treatment of advanced prostate cancer with a combination of hormone and chemotherapy does not lead to a cure, it may extend time to progression, particularly in patients with poor prognostic factors at the onset. In future phase III studies, the role of prognostic factors must be further classified in order to obtain meaningful results.</p>","PeriodicalId":77436,"journal":{"name":"The Prostate. Supplement","volume":"4 ","pages":"105-10"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pros.2990210516","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12741554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

A rationale for the use of non-steroidal anti-androgens in the management of prostate cancer. 使用非甾体抗雄激素治疗前列腺癌的基本原理。

The Prostate. Supplement Pub Date : 1992-01-01 DOI: 10.1002/pros.2990210513

R C Benson

引用次数: 6

Prostatic intraepithelial neoplasia (PIN): morphological clinical significance. 前列腺上皮内瘤变(PIN):形态学临床意义。

The Prostate. Supplement Pub Date : 1992-01-01 DOI: 10.1002/pros.2990210511

F K Mostofi, I A Sesterhenn, C J Davis

引用次数: 15

Quality of life in prostate cancer patients. 前列腺癌患者的生活质量。

The Prostate. Supplement Pub Date : 1992-01-01 DOI: 10.1002/pros.2990210523

S D Fosså, S Kaasa, F C da Silva, S Suciu, M W Hengeveld

{"title":"Quality of life in prostate cancer patients.","authors":"S D Fosså, S Kaasa, F C da Silva, S Suciu, M W Hengeveld","doi":"10.1002/pros.2990210523","DOIUrl":"https://doi.org/10.1002/pros.2990210523","url":null,"abstract":"QOL is a multidimensional approach describing the patient’s perception of life in terms of physical, psychological and social factors. These include physical symptoms, social functioning, emotional functioning, treatment satisfaction, sexualityhntimacy, future orientation, occupational functioning, spiritual life, and economic status. Historically, indicators of physical function and subjective toxicity have often been measured by physicians in clinical trials. As QOL is subjective, it seems appropriate that it should be assessed by the patient, through interviews or self-administered questionnaires [ 11. Ad hoc study-specific questionnaires, designed for a single study often suffer from inadequate psychometric properties and are not recommended. During the last decade several disease-specific questionnaires have been designed and validated, including the Symptom Distress Scale [2], Functional Living Index: Cancer [3], Medical Outcome Study [4], and the Rotterdam Symptom CheckList [ 5 ] . The authors recommend the EORTC Core Quality of Life Questionnaire [6] for all EORTC trials in order to gain experience with the instrument and to compare ratings between patient groups. Practical guidelines for QOL research are shown in Table I [7].","PeriodicalId":77436,"journal":{"name":"The Prostate. Supplement","volume":"4 ","pages":"145-8"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pros.2990210523","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12741560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 51

The natural history of locally confined prostate cancer: a review. 局部局限性前列腺癌的自然病史综述。

The Prostate. Supplement Pub Date : 1992-01-01 DOI: 10.1002/pros.2990210512

W R Fair

引用次数: 8

Prostate specific antigen in diagnosis, staging, and follow-up of prostate cancer. 前列腺特异性抗原在前列腺癌诊断、分期及随访中的作用。

The Prostate. Supplement Pub Date : 1992-01-01 DOI: 10.1002/pros.2990210520

E H Cooper

引用次数: 9

The management of incidental T1aG1 (TNM 1987) prostate cancer. 偶发性T1aG1 (TNM 1987)前列腺癌的治疗。

The Prostate. Supplement Pub Date : 1992-01-01 DOI: 10.1002/pros.2990210524

M S Soloway, J E Altwein